EUR/USD likely to find a peak near 1.25: UBS
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) stock has reached a 52-week low, touching down at $17.61. With a market capitalization of $1.17 billion and revenue growth of 25.74% last year, this price level marks a significant drop for the medical device company, which specializes in insulin delivery systems. Over the past year, Tandem’s stock has experienced a notable decline, with the 1-year change data reflecting a decrease of 46.91%. This downturn in stock value has caught the attention of investors who are closely monitoring the company’s performance amidst a challenging market environment. According to InvestingPro analysis, the stock appears undervalued at current levels, with strong liquidity indicated by a current ratio of 2.93. Subscribers can access 10 additional key insights and a comprehensive Pro Research Report for deeper analysis.
In other recent news, Tandem Diabetes Care reported a 20.6% increase in fourth-quarter 2024 revenue, reaching $252.4 million, which exceeded the consensus estimate of $249.7 million. However, the company’s guidance for 2025 projects only a 10-11% revenue increase, raising concerns among investors. This cautious outlook has led to several analyst downgrades. Morgan Stanley (NYSE:MS) downgraded the stock to Equalweight, reducing the price target to $22, citing modest growth expectations and competitive pressures. Similarly, Citi downgraded Tandem Diabetes from Buy to Neutral, lowering the price target to $24, due to uncertainties in future performance despite strong international sales. Bernstein also downgraded the stock to Market Perform with a revised price target of $25, pointing to market share loss and increased competition. On a positive note, Tandem’s Control-IQ+ technology showed promising results in a study, demonstrating significant A1C reductions for type 2 diabetes patients. The study highlighted improvements in glycemic control and user satisfaction, suggesting potential benefits for diabetes management.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.